GENB vs KMTS: fair value comparison
Generate Biomedicines, Inc. and Kestra Medical Technologies, Ltd. · Updated 2026-10-19
GENB has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. KMTS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, GENB currently ranks higher by quality score.
| GENB | KMTS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $12.09 | $27.24 |
| 12-month range | $12.09–$16.50 | $17.87–$28.68 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #187 of 301 Healthcare | #189 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Uptrend |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: GENB fair value analysis · KMTS fair value analysis